Kitov Product Pipeline The Kitov pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates that maintain advantages over current therapies or address unmet medical needs. Our pipeline consists of two therapeutic candidates:
- NT-219 – a first-in-class small molecule designed to overcome cancer drug resistance
- Consensi™ – a fixed-dose combination of two approved drug products that treats osteoarthritis pain and hypertension simultaneously. Kitov submitted a New Drug Application (NDA) in July 2017. The U.S. Food & Drug Administration (FDA) filed the NDA in September 2017, thereby accepting it for a full review.